Definium Therapeutics
DFTX
172 hedge funds and large institutions have $289M invested in Definium Therapeutics in 2024 Q4 according to their latest regulatory filings, with 37 funds opening new positions, 60 increasing their positions, 32 reducing their positions, and 20 closing their positions.
196% more call options, than puts
Call options by funds: $14.5M | Put options by funds: $4.88M
88% more repeat investments, than reductions
Existing positions increased: 60 | Existing positions reduced: 32
85% more first-time investments, than exits
New positions opened: 37 | Existing positions closed: 20
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
10% more funds holding
Funds holding: 157 → 172 (+15)
3% more capital invested
Capital invested by funds: $282M → $289M (+$7.25M)
4.22% less ownership
Funds ownership: 60.82% → 56.6% (-4.2%)
Top Buyers
| 1 |
BlackRock
New York
|
+$2.79M |
| 2 |
AIC
AWM Investment Company
New York
|
+$2.34M |
| 3 |
Marshall Wace
London,
United Kingdom
|
+$1.47M |
| 4 |
TCM
Tang Capital Management
San Diego,
California
|
+$1.38M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.37M |
Top Sellers
| 1 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$29.2M |
| 2 |
CC
Commodore Capital
New York
|
-$25.4M |
| 3 |
TLP
Tri Locum Partners
New York
|
-$5.79M |
| 4 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$3.56M |
| 5 |
ABG
Ally Bridge Group
New York
|
-$3.15M |
DFTX Hedge Fund Activity: Q4 2024 in Review
172 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Definium Therapeutics (DFTX) for Q4 2024, worth a combined $289M — up 2.6% from $282M a quarter earlier.
Buyers outnumbered sellers: 37 funds opened new DFTX positions and 20 closed out — a net gain of 17 holders — while 60 added to existing stakes and 32 trimmed.
The largest buyer was BlackRock, adding an estimated $2.79M. The largest seller was Deep Track Capital, cutting an estimated $29.2M.
- 172 institutional investors held Definium Therapeutics (DFTX) as of Q4 2024, up from 157 in Q3 2024.
- Funds reported $289M of Definium Therapeutics stock for Q4 2024, up 2.6% quarter-over-quarter.
- 37 funds opened new Definium Therapeutics positions in Q4 2024 and 20 closed out, a net change of +17 holders.
- The largest Definium Therapeutics buyer in Q4 2024 was BlackRock, an estimated $2.79M added.
- The largest Definium Therapeutics seller in Q4 2024 was Deep Track Capital, an estimated $29.2M sold.
Based on aggregated 13F filings for Q4 2024.